NeoGenomics appointed Warren Stone CEO. NeoGenomics stock fell 1.75 percent
Published on 10/08/2026 at 16:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- NeoGenomics appointed Warren Stone CEO effective January 4, 2027, while NEO stock fell 1.75 percent in the Lang & Schwarz session.
- Preliminary third-quarter revenue is expected at USD 209.0 million, with full-year guidance due for an update at the earnings call.
- NeoGenomics reported USD 201.66 million in second-quarter revenue, up 11.20 percent year over year.
- The next earnings report is scheduled for October 27, 2026, according to MarketBeat.
NeoGenomics stock (ISIN US64049M2098) was trading at EUR 14.04 at Lang & Schwarz on October 8, 2026 at 4:31 p.m. CEST, down 1.75 percent from EUR 14.29. On October 5, 2026, NeoGenomics appointed Warren Stone as CEO and a board member effective January 4, 2027.
Revenue points to stronger execution
The same October 5 release said preliminary third-quarter revenue is expected at USD 209.00 million and next-generation sequencing growth at 28.00 percent year over year. Management also said full-year revenue guidance is expected to rise at the midpoint on the third-quarter earnings call, while the current full-year revenue range remains USD 802.00 million to USD 806.00 million.
According to Investing.com on October 6, 2026, Needham raised its target from USD 19.00 to USD 22.00 and kept a Buy rating. The report cited third-quarter revenue of USD 209.00 million, above consensus of USD 206.00 million.
Three dated operating markers
On July 28, 2026, NeoGenomics reported second-quarter revenue of USD 201.66 million, up 11.20 percent year over year, according to MarketBeat. On August 26, 2026, the company received Medicare coverage for RaDaR ST, its third covered indication, as reported by Investing.com. On October 5, 2026, preliminary third-quarter revenue was set at USD 209.00 million, with NGS growth at 28.00 percent.
What dates matter next?
NeoGenomics is scheduled to report third-quarter 2026 results on October 27, 2026, before the market opens, according to MarketBeat. Warren Stone is due to become CEO and join the board on January 4, 2027, while Tony Zook becomes executive chair, according to the October 5 company release.
Valuation meets leadership change
BTIG upgraded NeoGenomics to Buy from Neutral and set a USD 28.00 target on October 6, 2026, according to Investing.com. The firm compared the stock's valuation at 3.00 times 2027 consensus revenue with roughly 11.00 times for specialty laboratory peers. That gap offers a clear explanation for the target changes, but the CEO handover adds an execution milestone to the October earnings event.
NEO stock trades below its yearly high
NeoGenomics had a market capitalization of USD 403.9 million and a 52-week range of USD 7.07 to USD 20.15 as of October 8, 2026. Its primary listing is Nasdaq, where the quote was USD 15.72 at 2:34 p.m. ET on October 8, 2026, down 1.57 percent from USD 15.97.
The further course of trading is shown by the continuously updated real-time quote of NeoGenomics stock.
NeoGenomics stock facts
- Company: NeoGenomics, Inc.
- ISIN: US64049M2098
- Ticker: NEO
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 8, 2026, 4:31 p.m. CEST): EUR 14.04
- Change versus prior close: minus 1.75 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 14.29
- Market capitalization: USD 403.9 million (as of October 8, 2026)
- 52-week range: USD 7.07-20.15 (as of October 8, 2026)
- Sector / Industry: Healthcare / Medical - Diagnostics and Research
- Next earnings date: October 27, 2026
Market context: Market report Nasdaq Composite.
